Free Trial
NASDAQ:VERA

Vera Therapeutics Q3 2024 Earnings Report

Vera Therapeutics logo
$20.86 -0.06 (-0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$21.04 +0.19 (+0.89%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics EPS Results

Actual EPS
-$0.85
Consensus EPS
-$0.64
Beat/Miss
Missed by -$0.21
One Year Ago EPS
N/A

Vera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vera Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Vera Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vera Therapeutics Earnings Headlines

Brokers Offer Predictions for VERA FY2026 Earnings
"I'm risking my reputation on this"
Crypto book predicted the last bull run (get it FREE now) This newly updated edition contains everything we've learned from interviewing the biggest names in crypto on our Crypto 101 podcast, which has over 17 million downloads and 600+ episodes. "Crypto Revolution" isn't just another book – it's your roadmap to potentially life-changing wealth in the current crypto bull run
Wedbush Equities Analysts Raise Earnings Estimates for VERA
Vera Therapeutics Inc.
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA), a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

View Vera Therapeutics Profile

More Earnings Resources from MarketBeat